

STAT Inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/S1DBB20BC6F0EN.html>

Date: January 2022

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: S1DBB20BC6F0EN

Abstracts

This report can be delivered to the clients within 2-3 working days

DelveInsight's, "STAT Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in STAT Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

STAT Inhibitors Understanding

STAT Inhibitors: Overview

Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. Signal transducer and activator of transcription (STAT) proteins represent novel therapeutic targets for the treatment of cancer. In particular, STAT γ 3 serves critical roles in several cellular processes, including the cell cycle, cell proliferation, cellular apoptosis and tumorigenesis. Persistent activation of STAT γ 3 has been reported in a variety of cancer types, and a poor prognosis of cancer may be associated with the phosphorylation level of STAT γ 3. Furthermore, elevated STAT γ 3 activity has been demonstrated in a variety

of mammalian cancers, both in vitro and in vivo. This indicates that STAT3 serves an important role in the progression of numerous cancer types. A significant obstacle in developing STAT3 inhibitors is the demonstration of the antitumor efficacy in in vivo systems and the lack of animal models for human tumors.

'STAT Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the STAT Inhibitors pipeline landscape is provided which includes the disease overview and STAT Inhibitors treatment guidelines. The assessment part of the report embraces, in depth STAT Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, STAT Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve STAT Inhibitors.

STAT Inhibitors Emerging Drugs Chapters

This segment of the STAT Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

STAT Inhibitors Emerging Drugs

Bardoxolone methyl: Reata Pharmaceuticals

Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug designation to

bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”). The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome. In April 2021, Reata Pharmaceuticals announced that the U.S. Food and Drug Administration (“FDA”) accepted for filing the New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.

SHR-0302: Jiangsu Hengrui Medicine Co./ Reistone Biopharma

SHR0302 is a potent and highly selective Janus kinase type 1 (JAK1) inhibitor, STAT3 transcription factor inhibitors and was in-licensed by Reistone from Jiangsu Hengrui Medicine Co., Ltd. Several late stage clinical studies are on-going with both oral and topical dosage forms for several immune-inflammatory diseases including Ulcerative Colitis, Crohn's disease, etc. The high selectivity of SHR0302 may potentially provide a favorable safety and efficacy profile compared to the pan-JAK inhibitors.

Further product details are provided in the report.....

STAT Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in STAT Inhibitors

There are approx. 25+ key companies which are developing the therapies for STAT Inhibitors. The companies which have their STAT Inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, Reata Pharmaceuticals.

Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

STAT Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

STAT Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses STAT Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging STAT Inhibitors drugs.

STAT Inhibitors Report Insights

STAT Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

STAT Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing STAT Inhibitors drugs?

How many STAT Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of STAT Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the STAT Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for STAT Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Bio-Path Holdings

Jiangsu Hengrui Medicine Co.

Reata Pharmaceuticals

Tvardi Therapeutics

Purple Biotech

Key Products

BP-1003

SHR-0302

Bardoxolone methyl

TTI-101

TTI-102

NT-219

Contents

Introduction

Executive Summary

STAT Inhibitors: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

SHR-0302: Jiangsu Hengrui Medicine Co.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early stage products (Phase I)

Comparative Analysis

TTI-101: Tvardi Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical stage products

Comparative Analysis

TTI-102: Tvardi Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

STAT Inhibitors Key Companies

STAT Inhibitors Key Products

STAT Inhibitors- Unmet Needs

STAT Inhibitors- Market Drivers and Barriers

STAT Inhibitors- Future Perspectives and Conclusion

STAT Inhibitors Analyst Views

STAT Inhibitors Key Companies

Appendix

I would like to order

Product name: STAT Inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/S1DBB20BC6F0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S1DBB20BC6F0EN.html>